Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Do‐Youn Oh(Seoul National University Hospital), Juan W. Valle(Cancer Research UK Manchester Institute), Choong‐kun Lee(Yonsei University), Suebpong Tanasanvimon(Thai Red Cross Society), Satoshi Shimizu(Saitama Cancer Center), В. В. Бредер, Piotr Potemski(Copernicus Memorial Hospital), Masafumi Ikeda(National Cancer Center Hospital East), Farshid Dayyani(University of California, Irvine), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Vikas Ostwal(Homi Bhabha National Institute), Felipe Rey(Dirección de Investigación y Desarrollo), Julie Wang(Shanghai Jiao Tong University), Magdalena Żotkiewicz(AstraZeneca (Poland)), Roopinder Gillmore, David Tougeron(Université de Poitiers), Mairéad G. McNamara(Australian and New Zealand Intensive Care Society), Mila Petrova, Gary L. Buchschacher(Kaiser Permanente), Ludovic Evesque(Centre Antoine Lacassagne), Aiwu Ruth He(Georgetown University), Joon Oh Park(Samsung Medical Center), Benjamin Tan(Washington University in St. Louis), Jen‐Shi Chen(Linkou Chang Gung Memorial Hospital), Arndt Vogel(Medizinische Hochschule Hannover), Howard A. Burris(Deaconess Hospital), Takuji Okusaka(National Cancer Centre Japan), Renata Zaucha(Gdańsk Medical University), Shukui Qin(Memorial Sloan Kettering Cancer Center), Mohamed Bouattour(Hôpital Beaujon), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), David B. Zhen(Fred Hutch Cancer Center), Ming‐Huang Chen(National Yang Ming Chiao Tung University), Jin Won Kim(Seoul National University Bundang Hospital), Hyosung Kim(AstraZeneca (Japan)), Li‐Tzong Chen(Kaohsiung Medical University), Masayuki Kitano(Wakayama Medical University), Claire Morgan(AstraZeneca (United States)), Nana Rokutanda(AstraZeneca (Japan)), Thatthan Suksombooncharoen(Chiang Mai University), Chigusa Morizane(Tokyo National Hospital), Juan E Cundom(Instituto de Diagnóstico e Investigaciones Metabólicas), Vineet Gupta(The University of Texas Medical Branch at Galveston)
Cited by 245
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k